Literature DB >> 32810491

microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.

Tayebeh Rezaei1, Maryam Hejazi2, Behzad Mansoori2, Ali Mohammadi3, Mohammad Amini2, Jafar Mosafer4, Sarah Rezaei2, Ahad Mokhtarzadeh5, Behzad Baradaran6.   

Abstract

Glioblastoma multiform (GBM) as the most frequent and lethal brain tumor is defined by aggressive invasiveness and considerable resistance to chemotherapy. The molecular mechanisms underlying GBM tumorigenesis still needs to be further investigated. Considering that, the current study was aimed to investigate the function of miR-181a in human glioblastoma cells in combination with carmustine. U373 cell line with the low expression levels of miR-181a was selected for functional investigations. MTT assay was used to determine cell viability and Annexin V/PI and DAPI staining were employed to evaluate apoptosis induction. Also, cell migration and cell cycle progression were investigated using wound healing test and flow cytometry, respectively. qRT-PCR was used for the quantification of gene expression. MTT assay results revealed that miR-181a replacement increased the sensitivity of U373 cells to low doses of carmustine. Moreover, miR-181a was shown to increase the sub G1 cell cycle arrest and apoptosis induction by carmustine via regulating the expression of related genes including caspase-9, Bcl-2, and SIRT1. Furthermore, this miRNA combined with carmustine suppressed cell migration via downregulation of MMP-2 and Bach1 and reduced the clonogenic ability of U373 cells. Additionally, miR-181a-mediated downregulation of AKT1 implied that this miRNA could inhibit cell proliferation by modulating PI3K/AKT signaling pathway. In conclusion, the findings of this study suggest that miR-181a replacement, regarding its tumor-suppressive effects and sensitization of glioblastoma cells to carmustine, could be considered as a potential therapeutic strategy to improve the efficiency of glioblastoma chemotherapy.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AKT signaling; Carmustine; Glioblastoma; miR-181a; microRNA replacement therapy

Mesh:

Substances:

Year:  2020        PMID: 32810491     DOI: 10.1016/j.ejphar.2020.173483

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1.

Authors:  Tingting Lou; Luqing Zhang; Zongshan Jin; Chundi Miao; Jinqiu Wang; Kongliang Ke
Journal:  Open Med (Wars)       Date:  2022-04-28

Review 2.  Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics.

Authors:  Ming-Hsien Chan; Wen-Tse Huang; Aishwarya Satpathy; Ting-Yi Su; Michael Hsiao; Ru-Shi Liu
Journal:  Pharmaceutics       Date:  2022-02-21       Impact factor: 6.321

Review 3.  Research progress of anti-glioma chemotherapeutic drugs (Review).

Authors:  Yi-Shu Zhou; Wei Wang; Na Chen; Li-Cui Wang; Jin-Bai Huang
Journal:  Oncol Rep       Date:  2022-04-01       Impact factor: 3.906

Review 4.  NcRNAs: Multi‑angle participation in the regulation of glioma chemotherapy resistance (Review).

Authors:  Zhaomu Zeng; Yueyue Chen; Xiuchao Geng; Yuhao Zhang; Xichao Wen; Qingyu Yan; Tingting Wang; Chen Ling; Yan Xu; Junchao Duan; Kebin Zheng; Zhiwei Sun
Journal:  Int J Oncol       Date:  2022-05-04       Impact factor: 5.884

Review 5.  The Role of microRNAs in Multidrug Resistance of Glioblastoma.

Authors:  Parvaneh Mahinfar; Behnaz Mansoori; Davoud Rostamzadeh; Behzad Baradaran; William C Cho; Behzad Mansoori
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

6.  MicroRNA-143 Sensitizes Cervical Cancer Cells to Cisplatin: a Promising Anticancer Combination Therapy.

Authors:  Yalda Baghay Esfandyari; Mohammad Amin Doustvandi; Mohammad Amini; Behzad Baradaran; Sheyda Jodeiry Zaer; Nazila Mozammel; Mehdi Mohammadzadeh; Ahad Mokhtarzadeh
Journal:  Reprod Sci       Date:  2021-02-10       Impact factor: 3.060

Review 7.  Targeting Glioblastoma: The Current State of Different Therapeutic Approaches.

Authors:  Imran Khan; Sadaf Mahfooz; Elif Burce Elbasan; Busra Karacam; Mustafa Namik Oztanir; Mustafa Aziz Hatiboglu
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.